Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 644 (LINC00644) is a member of the long intergenic non-coding RNA (lincRNA) family, characterized by autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap with protein-coding genes[1][3][5][7]. LincRNAs are a subclass of long non-coding RNAs (lncRNAs) and are known for roles in regulating gene expression, chromatin remodeling, and influencing transcription, often with tissue-specific expression patterns[5][7]. While some long intergenic non-coding RNAs have been implicated in cancer and disease, there is currently insufficient published evidence to assign LINC00644 as a therapeutic target or as directly involved in specific disease processes based on the cited sources[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 644 (LINC00644).